Semaglutide and Weight Loss: What Actually Happens in Your Body
Understand the mechanism behind GLP-1 receptor agonists, why they work so well, and what to expect in your first 12 weeks.
Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. GLP-1 — glucagon-like peptide 1 — is a hormone your gut naturally releases after eating. It signals your pancreas to release insulin, tells your liver to stop releasing glucose, and — most importantly for weight loss — travels to your brain's hypothalamus to signal satiety.
The Appetite Mechanism
When semaglutide binds to GLP-1 receptors in the brain, it mimics this satiety signal — but far more potently and for much longer than the naturally occurring hormone. The half-life of endogenous GLP-1 is about two minutes. Semaglutide's half-life is approximately one week. The result is a sustained reduction in hunger that most patients describe as "food noise" going quiet.
What to Expect Week by Week
Weeks 1–4: The starting dose (0.25 mg weekly) is primarily a tolerance phase. Side effects — usually mild nausea and fatigue — are most common here. Most patients report modest appetite changes but not dramatic weight loss yet.
Weeks 5–12: Dose increases toward the therapeutic range. By week 12, clinical trials show average weight loss of 6–8% of starting body weight. The STEP trials consistently demonstrate 10–15% total body weight reduction over 68 weeks.
Beyond the Scale
The benefits extend well beyond weight. Semaglutide improves insulin sensitivity, reduces visceral adiposity (the dangerous fat surrounding organs), lowers blood pressure, and has demonstrated cardiovascular protection in the SUSTAIN-6 trial. Your 877PEPTIDE physician monitors these metabolic markers throughout your program.